Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) had its price target lowered by analysts at HC Wainwright from $14.00 to $12.00. They now have a "buy" rating on the stock.
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) is now covered by analysts at BTIG Research. They set a "buy" rating and a $12.00 price target on the stock.